Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

被引：2

作者：

Pinaire, Jane A. ^{[1
]}

Miller, Anne Reifel ^{[1
]}

Gregoire, Francine M.

机构：

[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

PPAR RESEARCH | 2008年 / 2008卷

关键词：

D O I：

10.1155/2008/786359

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页数：2

共 7 条

[1] PPAR dual agonists: Are they opening Pandora's box? [J].

Balakumar, Pitchal ;

Rose, Madhankumar ;

Ganti, Subrahmanya S. ;

Krishan, Pawan ;

Singh, Manjeet .

PHARMACOLOGICAL RESEARCH, 2007, 56 (02) :91-98

[2] PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome [J].

Fievet, Catherine ;

Fruchart, Jean-Charles ;

Staels, Bart .

CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) :606-614

[3]

ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0

[4] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[5] Safety issues and prospects for future generations of PPAR modulators [J].

Rubenstrunk, Anne ;

Hanf, Remy ;

Hum, Dean W. ;

Fruchart, Jean-Charles ;

Staels, Bart .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08) :1065-1081

[6] The next generation of PPAR drugs: Do we have the tools to find them? [J].

Shearer, Barry G. ;

Billin, Andrew N. .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08) :1082-1093

[7] Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist [J].

Waites, Crystal R. ;

Dominick, Mark A. ;

Sanderson, Thomas P. ;

Schilling, Beth E. .

TOXICOLOGICAL SCIENCES, 2007, 100 (01) :248-258

← 1 →